Crizotinib CAS 877399-52-5 Assay ≥99.0% API Factory High Quality
Shanghai Ruifu Chemical Co., Ltd. ke moetsi ea ka sehloohong oa Crizotinib (CAS: 877399-52-5) ka boleng bo phahameng.Ruifu Chemical e ka fana ka lits'ebeletso tsa lefats'e ka bophara, theko ea tlholisano, litšebeletso tse ntle haholo, tse nyane le tse ngata tse fumanehang.Reka Crizotinib,Please contact: alvin@ruifuchem.com
| Lebitso la Lik'hemik'hale | Crizotinib |
| Litlhaloso tse tšoanang | Xalkori;PF-02341066;Crozotinib;Crizotinib Xalkori;3- [1-(2,6-Dichloro-3-Fluoro-phenyl)-ethoxy] -5-(1-Piperidin-4-yl-1H-pyrazol-4-yl) -pyridin-2-ylamine;(R) -3-[1-(2,6-Dichloro-3-Fluorophenyl) ethoxy] -5-(1-Piperidin-4-yl-1H- pyrazol-4-yl)pyridin-2-ylamine |
| Nomoro ea CAS | 877399-52-5 |
| Boemo ba Setoko | Ka Setokong, Phatlalatso e Eketsehile ho fihla ho Makholo a Lik'hilograma |
| Foromo ea limolek'hule | Setšoantšo sa C21H22Cl2FN5O |
| Boima ba Molek'hule | 450.34 |
| Melting Point | 192 ℃ |
| Botenya | 1.47±0.10 g/cm3 |
| Mocheso oa polokelo | Mocheso oa Kamore |
| Tšimoloho | Shanghai, China |
| Brand | Ruifu Chemical |
| Ntho | Litlhaloso |
| Ponahalo | Phofo e tšoeu ho isa ho e tšoeu |
| Boitsebiso | Ka IR, HPLC |
| Ho Hlakola ha Tharollo | Ikamahanye le Maemo |
| Tahlehelo ka ho Omisa | ≤1.00% |
| Masalla a ho Ignition | ≤0.50% |
| Litšila Tse Amanang | (ka HPLC) |
| Tšilafalo e le Mong | ≤0.50% |
| Litšila ka Kakaretso | ≤1.00% |
| Litšepe tse boima | ≤20ppm |
| Tlhahlobo | ≥99.0% |
| Metsoako e setseng | Kopana le Litlhophiso |
| Shelf Life | Likhoeli tse 24 |
| Tekanyetso ea Teko | Maemo a Khoebo |
Sephutheloana:Botlolo, Aluminium foil bag, 25kg/Cardboard Drum, kapa ho ea ka tlhokahalo ea moreki.
Boemo ba polokelo:Boloka setshelo se kwetswe ka thata mme o se boloke sebakeng se phodileng, se omeletseng (2~8℃) le se nang le moya o hlwekileng hole le dintho tse sa dumellaneng.Sireletsa leseli le mongobo.
Ho tsamaisa ka sekepe:Tsamaisa lefatšeng ka bophara ka sefofane, ka FedEx / DHL Express.Fana ka thomello e potlakileng le e tšepahalang.
Tlhaloso ea Tšireletseho 24/25 - Qoba ho kopana le letlalo le mahlo.
Li-ID tsa UN UN 3077 9 / PGIII
WGK Jeremane 3
HS Code 2933990099
Kotsi Class TSOHLE
Crizotinib (CAS 877399-52-5), (Crizotinib, Xalkori R), ke ATP e matla le e khethang tlhōlisano e nyenyane ea molek'hule inhibitor ea ALK le c-Met.Ka Phato 2011, United States FDA e amohetse Crizotinib bakeng sa kalafo ea anaplastic lymphoma kinase (ALK) e ile ea hlophisa bocha mofets'e oa mofetše o seng o nyane oa lisele tsa matšoafo (NSCLC).Crizotinib ke ATP competitive inhibitor ea tyrosine kinases c-MET (Mesenchymal-Epithelial Transition Factor) kinase (cellular IC50 = 8 nM) le ALK (cellular IC50 = 20 nM), tseo ka bobeli e leng lipheo tsa bohlokoa bakeng sa chemotherapy ea kankere.Ha crizotinib e ne e lekoa bakeng sa selectivity khahlanong le li-kinases tse ling ho ile ha fumanoa hore e na le enzyme IC50's ka har'a li-multiples tsa 100 tsa c-MET bakeng sa 13 ea 120 kinases e lekiloeng.Litlhahlobong tsa cellular, crizotinib e ile ea fumanoa e thibela RON (recepteur d'origine nantais) kinase e nang le fensetere ea 10-fold selectivity holim'a c-MET.
Crizotinib (PF-02341066) Crizotinib ke c-Met e matla le ALK inhibitor, litekanyetso tsa IC50 ka har'a tlhahlobo ea lisele e ne e le 11 nM le 24 nM, ka ho latellana.Hape ke inhibitor e matla ea ROS1 e nang le boleng ba Ki bo ka tlase ho 0.025 nM.Crizotinib e ka etsa hore autophagy e kenelle liseleng tse fapaneng tsa kankere ea matšoafo ka ho thibela tsela ea STAT3.
Crizotinib ke inhibitor e matla le e khethiloeng ka bobeli ea mesenchymal-epithelial transition factor (c-MET) kinase le anaplastic lymphoma kinase (ALK).Crizotinib ke moemeli oa antitumor o ka bang teng.Ka Phato 2011, United States FDA e amohetse crizotinib bakeng sa kalafo ea anaplastic lymphoma kinase (ALK) e ile ea hlophisa bocha mofets'e oa mofetše o se nang lisele tse nyane (NSCLC).
Crizotinib (Xalkori(R), Pfizer), e amohetsoeng ka 2011, e bile inhibitor ea pele e amohetsoeng e shebileng anaplastic lymphoma kinase (ALK).ROS protooncogene 1-encoded kinase (ROS1) ea sehlopha sa tyrosine kinase insulin receptor le MET proto-oncogene-encoded kinase ea sehlopha sa hepatocyte growth factor receptor (HGFR) ke kinase e meng e lebisitsoeng ke crizotinib.Ha e amoheloa ka 2011, crizotinib e bile eona ea pele. lithethefatsi tse tobaneng le bakuli ba NSCLC.Leha ho le joalo, ho hanyetsa crizotinib hangata ho ne ho hlokomeloa hoo e ka bang likhoeli tsa 8 ka mor'a kopo ea pele 'me ba fetang halofo ea bakuli ba tšoaroang ke crizotinib ba ile ba ba le litla-morao tsa mala.Ka 2016, Crizotinib e ile ea amoheloa hape bakeng sa NSCLC e ntle ea ROS1 ke FDA.
Crizotinib (Xalkori) ke oral receptor tyrosine kinase inhibitor e bontšitsoeng bakeng sa phekolo ea bakuli ba nang le kankere e tsoetseng pele kapa ea metastatic e seng e nyenyane ea kankere ea matšoafo ea sele (NSCLC).Litla-morao tse tloaelehileng ka tšebeliso ea Xalkori li kenyelletsa tšoaetso e phahameng ea phefumoloho, ho nyekeloa ke pelo, ho hlatsa, bohloko ba ka mpeng, ho fokotseha ha takatso ea lijo, ho hlobaela, ho tsekela, mokhathala, lets'ollo, ho patoa, lekhopho kapa ho hlohlona, matšoao a batang ( nko e koetsoeng, ho ethimola, 'metso), ho tsieleha kapa ho tsokotsa, kapa ho ruruha matsohong kapa maotong.
